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Abstract 
Purpose: Though the complexation of ciprofloxacin with metal cations has been extensively 
studied, the effect of this complexation on the aqueous solubility of ciprofloxacin which is an 
important factor affecting drug distribution has not been well documented. We have thus set out 
in this study to investigate the aqueous solubility of ciprofloxacin in the presence of metal 
cations. 
Method: The measurements were done spectrophometrically after shaking ciprofloxacin 
alone or in the presence of varying amounts of different metal cations for five hours to attain 
equilibrium. The amount of ciprofloxacin in the saturated solution in each case was then 
measured spectrophotometrically 
Results:  The solubility of ciprofloxacin in 0.05M H2SO4 at 37.0 ± 0.20C was 46.65 mgml-1 
(0.12M). Except for magnesium sulphate, all the cations investigated progressively increased 
the aqueous solubility of ciprofloxacin. Ferrous ion had the greatest increase. It was followed 
by ferric, calcium and aluminium ions. Potassium and sodium ions had very slight increase in 
ciprofloxacin solubility. As the amount of magnesium sulphate increased, the aqueous 
solubility of ciprofloxacin increased slightly initially but then decreased progressively. 
Conclusion: The observed solubility profiles can be attributed to the type and extent of 
complexes formed between ciprofloxacin and the metal cations. This increase in the aqueous 
solubility of ciprofloxacin can have profound effect on the enteric absorption of ciprofloxacin 
and on its antibacterial activity when these metal cations are present, and may contribute to 
the observed poor availability and antibacterial activity of ciprofloxacin when co-administered 
with these cations.  
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Introduction 
Ciprofloxacin is a member of the fluoroquinolone 
class of synthetic antimicrobial agents that has 
broad spectrum of activity against both Gram-
positive and Gram-negative organisms (1). It is 
rapidly and relatively well absorbed from the oral 
route, penetrates and distributes well into tissues 
and thus reaches concentrations in serum, body 
fluid and tissues well above the minimum 
inhibitory concentrations (MICs). (2 - 4) 
Despite these desirable pharmacokinetic nd 
antimicrobial profiles, it has been observed that 
co-administration with magnesium- and 
aluminium- containing anti-acids resulted in 
nearly complete loss of activity. Reduced bio-
availability was also reported when it was co-
administered with preparations containing iron 
and multivitamins containing zinc (5 – 11). 
Different metal cations have also been found to 
reduce its antibacterial activity to varying extents 
in-vitro (12 – 14). 
 
Because ciprofloxacin is widely used to treat 
resistant microbial infections (15), there has 
been obvious concern about its interaction with 
metal cations and how this affects its bio-
availability and antimicrobial activity when they 
are co-administered. Such concomitant 
administration may not be avoidable. Several 
reasons ranging from complexation of 
ciprofloxacin with cations in the gut thus 
reducing its enteric absorption (5, 9), formation 
of insoluble, unabsorbable and antibacterially 
inactive chelate complexes, to formation of 
complexes which are less able to be taken up by 
bacteria than the free drug have been suggested 
to explain the observed effects. In all these 
considerations, the gastric absorption of 
ciprofloxacin, its tissue penetration and its 
penetration of the bacterial cell wall are 
important factors affecting its bio-availability and 
antimicrobial activity. 
The complexation of ciprofloxacin with the metal 
cations and how this complexation affects 
ciprofloxacin bioavailability and antimicrobial 
activity have been extensively studied. (16 – 24) 
However, it is not still clear how ciprofloxacin – 
metal cation interaction can account for the 
biopharmaceutical observations. We have 
therefore set out in this study to investigate the 
aqueous solubility of ciprofloxacin alone and 
compare it with its solubility in the presence of 
compounds containing various  metal cations 
used in pharmaceutical practice  and at a 
simulated pH of the stomach.. The implication of 
the effect of solubility of ciprofloxacin on its 





Thermostated shaker bath (Gallenkamp, UK) set 
at 37 ± 0.20C was used to shake the 
ciprofloxacin and ciprofloxacin metal cation 
solutions. Ultraviolet/Visible spectrophotometer 
(Ultrospec 3000, Pharmacia Biotech, 
Cambridge, UK) was used to take all the 




Pure ciprofloxacin hydrochloride monohydrate 
(Sam Pharmaceuticals, Nigeria) sulphuric acid 
(BDH Chemicals, UK), ferric ammonium citrate 
(May and Baker, India); ferrous sulphate 
heptahydrate, aluminium hydroxide, magnesium 
sulphate, calcium carbonate, and potassium 
chloride (Merck, Germany) and sodium 
bicarbonate (Halewood Chemicals, UK) were 




De-ionised water was used to prepare a stock 
solution of 0.05molL-1 sulphuric acid. This 
solution was used to prepare the solutions of 
ciprofloxacin and the metal cations. The 
solubility of ciprofloxacin alone was determined 
by weighing ciprofloxacin powder accurately into 
5ml 0.05molL-1 sulphuric acid in a 20ml 
stoppered volumetric flask. This was then put in 
a thermostated shaker bath set at 37 ± 0.20C 
and shaken for five hours to attain equilibrium. 
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An aliquot of the supernatant of the saturated 
solution was diluted serially with 0.05molL-1 
sulphuric acid to produce a solution whose 
absorbance was measured at 277nm 
(wavelength of maximum absorption i.e. at λmax = 
277nm). The concentration of ciprofloxacin 
corresponding to this final solution was 
interpolated from Beer’s plot of ciprofloxacin in 
0.05molL-1 sulphuric acid previously prepared at 
277nm. From the dilution factor, the original 
concentration of the saturated solution and 
hence the solubility of ciprofloxacin was 
calculated.  
The procedure was repeated in the presence of 
varying amounts of the different metal cations. 
Except for the determinations in the presence of 
magnesium sulphate where final absorbance 
readings were taken at 277nm, absorbance 
readings for the other determinations in the 
presence of other metal cations were taken 
between 360 and 370nm.  
Beer’s plot for ciprofloxacin in each ciprofloxacin-
metal ion complex was made. This was done by 
taking varying weights of ciprofloxacin with the 
metal cation in 0.05molL-1 sulphuric acid and 
measuring their absorbances at the respective 
λmax between 360nm and 370nm. The 
concentration of ciprofloxacin in each 
ciprofloxacin – metal ion complex was 
interpolated from the Beer’s plot for the 
respective complex. 
Results and Discussion 
0.05molL-1 sulphuric acid  was used to mimic the 
acidity of the stomach. Some of the metal 
cations formed coloured solutions in 0.1molL-1 
hydrochloric acid hence it was not used because 
it would significantly interfere with the spectral 
measurements. Shaking at 37 ± 0.20C for five 
hours was to mimic human gastrointestinal tract 
motility, body temperature and to attain  
equilibrium more readily. 
In the medium used here, Beer’s law was 
obeyed for ciprofloxacin at its λmax of 277nm. In 
the presence of metal cations studied (except for 
magnesium sulphate), ciprofloxacin formed 
complexes that absorbed radiation at longer 
wavelengths. Thus, to reduce the spectral 
interference of the metal cations, determinations 
in the presence of metal cations were made at 
longer wavelengths (between 360 and 370nm). 
In the presence of each metal cation, Beer’s law 
was obeyed for ciprofloxacin. 
The solubility of ciprofloxacin in the medium 
used here is 46.65mgml-1 (0.12M). This value 
shows that the drug has appreciable solubility at 
the pH of the stomach. Thus, with an adult dose 
of 250mg ciprofloxacin, dissolution of the drug 
would take place readily. Ross et al (25) have 
reported the solubility of 6.9 mgml-1 at 37oC for 
ciprofloxacin at a pH of 5. 
In the presence of drugs containing metal 
cations (except for magnesium sulphate), 
ciprofloxacin formed soluble complexes in acidic 
medium. The solubility of ciprofloxacin in the 
presence of varying amounts of metal cations 
are shown in Fig 1. In the presence of 
magnesium sulphate, there was no shift in the 
λmax of ciprofloxacin. This signified that no 
complex must have been formed. Sanchez et al 
(17) have reported a similar trend. They 
concluded that ciprofloxacin does not form co-
ordination complex with polyvalent cations in 
acid medium. It was observed that in the 
presence of magnesium sulphate, the solubility 
of ciprofloxacin increased slightly from 
46.65mgml-1 (0.12M) to 50mgml-1 (0.13M) as the 
amount of magnesium sulphate increased 
initially. Thereafter, the solubility of ciprofloxacin 
decreased progressively with increase in the 
amount of magnesium sulphate. At higher 
amounts of magnesium sulphate, there was 
precipitation. Ross et al (16) have also reported 
a similar decrease in the solubility of 
lomefloxacin (an analogue of ciprofloxacin) in 
acidic medium in the presence of Bi3+. They 
attributed this to formation of type B complex of 
Higuchi and Connors (26). A similar factor may 
be responsible for the observed trend here for 
ciprofloxacin in the presence of Mg2+. Moreover, 
Turel et al (24) have shown that ciprofloxacin 
forms an adduct with magnesium sulphate in 
which magnesium is not bonded to the quinolone 
molecule but rather, the magnesium ion is co-
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ordinated by six water molecules forming 
[Mg(H2O)6]2+ cation with a nearly regular  
octahedral geometry. They reported that it was 
the only example of a metal-quinolone ionic 
compound with the water molecules co-
ordinated to the metal. The precipitation 
observed in this study may be of the magnesium 
adduct formed. The co-ordination of six water 
molecules to magnesium ion in aqueous solution 
of this adduct ties up water molecules. This will 
make less water molecules available to 
solubilize ciprofloxacin. Also, the lattice structure 
of this adduct is different from that of the other 
co-ordination complexes of ciprofloxacin (18) 
hence the different behaviour in its aqueous 
solubility. 
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In the presence of the metal cations where there 
was a shift in the λmax of ciprofloxacin to longer 
wavelengths thus indicating metal cation co-
ordination to ciprofloxacin, the complexes 
formed (hence the amount of ciprofloxacin in 
them) were progressively more soluble as the 
amount of metal cations increased. However, the 
extent of increase in solubility of ciprofloxacin 
was different in the presence of different metal 
cations. 
Ferrous sulphate caused the greatest increase in 
solubility of ciprofloxacin at all levels of the 
amount of metal cations. This was followed by 
ferric ammonium citrate, calcium carbonate and 
aluminium hydroxide. Potassium chloride and 
sodium bicarbonate caused similar but very little 
increases in the solubility of ciprofloxacin in 
acidic medium. Thus, the divalent and trivalent 
cations caused greater increases in the aqueous 
solubility of ciprofloxacin while the monovalent 
cations caused very slight increases. The 
increase in solubility of ciprofloxacin in the 
presence of these metal cations may be due to 
the formation of ionic and hydrated complexes 
which are more hydrophilic than ciprofloxacin. 
Ciprofloxacin has been reported to form metal 
cation complexes which have varying numbers 
of water of hydration (18 - 23). 
When a drug is administered as a tablet, the 
tablet will first disintegrate in the stomach and be 
dissolved before it is absorbed. To penetrate the 
gastrointestinal membranes of the stomach, the 
drug must possess appreciable lipophilicity (27). 
For a drug like ciprofloxacin that possesses a 
good dissolution and lipophilic properties and 
can thus penetrate the membranes of the 
stomach, any factor that enhances its hydrophilic 
properties will reduce its lipophilicity and thus 
decrease its penetration through the membranes 
of the stomach. This in turn will reduce the 
amount of the drug that will be absorbed and 
hence decrease bioavailability. 
The general implication of the increasing 
solubility of ciprofloxacin in the presence of the 
metal cations is the decrease in bioavailability 
under such conditions. However, from this study, 
different cations will elicit this effect to different 
extents. Ferrous sulphate will have a more 
profound effect while the monovalent cations will 
have less effect. The same decreased 
lipophilicity of ciprofloxacin in the presence of 
metal cations will account for the decreased 
antimicrobial activity of ciprofloxacin in the 
presence of metal cations as ciprofloxacin will be 
less able to penetrate the bacterial cell walls in 
such cases. From this study, the decrease in 
antimicrobial activity will vary to different extents 
in the presence of different  metal cations and 





We propose that the reduced bio-availability of 
ciprofloxacin in the presence of metal cations is 
as a result of the formation of more ionic and 
water soluble complexes. This will make it to be 
less absorbable and also less antibacterially 
active. 
 
Ferrous sulphate, ferric ammonium citrate, 
calcium carbonate and aluminium hydroxide 
form water soluble complexes in acid medium 
with ciprofloxacin. This complexation will have 
profound effects on both the bioavailability and 
antibacterial activity of ciprofloxacin. It is 
therefore suggested that co-administration of 
ciprofloxacin with these metal cations be 
discouraged as this will compromise the 
therapeutic usefulness of ciprofloxacin. Sodium 
bicarbonate and potassium chloride showed little 
increase on the solubility of ciprofloxacin in acid 
medium and will have less adverse effects when 
co-administered with ciprofloxacin.  
Magnesium sulphate does not form any soluble 
complex with ciprofloxacin in acid medium. Thus, 
this in-vitro study predicts that in this medium, 
magnesium sulphate may not adversely affect 
the bioavailability and antibacterial activity of 
ciprofloxacin. However, because in-vivo 
conditions were not replicated completely, 
therapeutic observations may be different.  
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